Arch Biopartners Inc (ARCH) - Total Assets

Latest as of September 2025: CA$104.53K CAD

Based on the latest financial reports, Arch Biopartners Inc (ARCH) holds total assets worth CA$104.53K CAD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Arch Biopartners Inc - Total Assets Trend (1997–2025)

This chart illustrates how Arch Biopartners Inc's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

Arch Biopartners Inc - Asset Composition Analysis

Current Asset Composition (September 2025)

Arch Biopartners Inc's total assets of CA$104.53K consist of 100.0% current assets and 0.0% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$0.00 2.0%
Accounts Receivable CA$0.00 0.0%
Inventory CA$0.00 0.0%
Property, Plant & Equipment CA$0.00 0.0%
Intangible Assets CA$0.00 0.0%
Goodwill CA$0.00 0.0%

Asset Composition Trend (1997–2025)

This chart illustrates how Arch Biopartners Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Arch Biopartners Inc's current assets represent 100.0% of total assets in 2025, an increase from 3.5% in 1997.
  • Cash Position: Cash and equivalents constituted 2.0% of total assets in 2025, up from 1.3% in 1997.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 1997.
  • Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.

Arch Biopartners Inc Competitors by Total Assets

Key competitors of Arch Biopartners Inc based on total assets are shown below.

Arch Biopartners Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.03 0.18 0.35
Quick Ratio 0.03 0.18 0.35
Cash Ratio 0.00 0.00 0.00
Working Capital CA$-3.88 Million CA$-4.35 Million CA$-1.40 Million

Arch Biopartners Inc - Advanced Valuation Insights

This section examines the relationship between Arch Biopartners Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio -
Latest Market Cap to Assets Ratio 211.24
Asset Growth Rate (YoY) -88.8%
Total Assets CA$104.53K
Market Capitalization $22.08 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Arch Biopartners Inc's assets at a significant premium (211.24x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: Arch Biopartners Inc's assets decreased by 88.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Arch Biopartners Inc (1997–2025)

The table below shows the annual total assets of Arch Biopartners Inc from 1997 to 2025.

Year Total Assets Change
2025-09-30 CA$104.53K -88.83%
2024-09-30 CA$935.62K -20.11%
2023-09-30 CA$1.17 Million +88.40%
2022-09-30 CA$621.64K -76.70%
2021-09-30 CA$2.67 Million +259.94%
2020-09-30 CA$741.30K +30.52%
2019-09-30 CA$567.98K -15.57%
2018-09-30 CA$672.69K +890.16%
2017-09-30 CA$67.94K -70.08%
2016-09-30 CA$227.03K -65.05%
2015-09-30 CA$649.50K +60.06%
2014-09-30 CA$405.79K +1001.91%
2013-09-30 CA$36.83K -60.75%
2012-09-30 CA$93.81K -57.75%
2011-09-30 CA$222.04K -58.52%
2010-09-30 CA$535.28K +33355.19%
2009-09-30 CA$1.60K -99.80%
2008-09-30 CA$797.32K -16.98%
2007-09-30 CA$960.41K +0.74%
2006-09-30 CA$953.38K -17.63%
2005-09-30 CA$1.16 Million -15.87%
2004-09-30 CA$1.38 Million -16.02%
2003-09-30 CA$1.64 Million +2668.41%
2002-09-30 CA$59.18K -16.12%
2001-09-30 CA$70.56K -97.02%
2000-09-30 CA$2.37 Million +87.01%
1999-09-30 CA$1.26 Million +575.79%
1998-09-30 CA$187.16K -47.71%
1997-09-30 CA$357.96K --

About Arch Biopartners Inc

V:ARCH Canada Biotechnology
Market Cap
$22.08 Million
CA$30.52 Million CAD
Market Cap Rank
#27699 Global
#908 in Canada
Share Price
CA$0.46
Change (1 day)
-5.15%
52-Week Range
CA$0.46 - CA$1.91
All Time High
CA$5.00
About

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more